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Background: Breast cancer is a prevalent disease and a leading cause of cancer death in 
women. Over 70% of breast cancers express estrogen receptor α(ERα). In ERα-positive 
breast cancers, estradiol is a key regulator of cell proliferation and survival. Treatment 
options for ERα-positive breast cancer patients include endocrine therapies that inhibit 
ERα signaling, either by antagonizing ligand binding to ERα, downregulating ERα or 
suppressing estrogen production. However, endocrine therapies do not always work in 
these patients, despite the expression of ERα in their tumors. Thus, resistance to 
endocrine therapies remains a major challenge in the treatment of ERα-positive breast 
cancers. Tumor protein 53-induced nuclear protein 1 (TP53INP1) is a key stress protein 
with tumor suppressor function. Several studies have demonstrated TP53INP1 
downregulation in many cancers. In this study, we investigated the correlations of 
TP53INP1 mRNA expression in breast cancer tissues with prognosis and the correlations 
of microRNAs that regulate TP53INP1 expression in breast cancer patients with long 
follow-up. 
Methods:A total of 453 invasive breast cancer tissues were analyzed for TP53INP1 
mRNA expression. We examined correlations of clinicopathological factors and 
expression levels of TP53INP1 mRNA in these samples. The expressions of miR-155, 
miR-569 and markers associated with tumor-initiating capacity were also analyzed. The 
median follow-up period was 9.0 years. 
Results:We found positive correlations between low expression of TP53INP1 mRNA and 
shorter disease-free survival and overall survival in breast cancer patients (P=0.0002 
andP<0.0001, respectively), as well as in estrogen receptor α(ERα)-positive patients 
receiving adjuvant endocrine therapy (P=0.01 andP=0.0008, respectively). No 
correlations were found in ERα-negative patients. Low TP53INP1 mRNA levels 
positively correlated with higher grade and ERα-negativity. Multivariate analysis 
indicated that TP53INP1 mRNA level was an independent risk factor for overall survival 
both in overall breast cancer patients (hazard ratio, 2.13; 95% confidence interval, 1.17–
3.92) and ERα-positive patients (hazard ratio, 2.34; 95% confidence interval, 1.18–4.64). 
Conclusions:We show that low expression of TP53INP1 is an independent factor of poor 
prognosis in breast cancer patients, especially ERα-positive patients.TP53INP1 might 
be a promising candidate biomarker and therapeutic target in ERα-positive breast 
cancer patients. 
